By Finance Pulse in BMY —

Bristol Myers Squibb's Injectable Opdivo Gets FDA Nod

FDA approval for Bristol Myers Squibb's injectable Opdivo enhances patient convenience and protects future sales as patent expiration nears.

Illustration of Opdivo injection vial with a futuristic and sleek design, highlighting innovation in
Bristol Myers Squibb's Injectable Opdivo Gets FDA Nod

FDA approval of injectable Opdivo provides Bristol Myers Squibb with a strategic advantage as it approaches a patent expiration.

Source